DiscoverPeerVoice Immunology & Infectious Disease AudioJAK Inhibitors in the Management of Dermatologic Disorders: Clinical Implications of the Latest Safety Findings
JAK Inhibitors in the Management of Dermatologic Disorders: Clinical Implications of the Latest Safety Findings

JAK Inhibitors in the Management of Dermatologic Disorders: Clinical Implications of the Latest Safety Findings

Update: 2022-03-29
Share

Description

Visit https://www.peervoice.com/PDW860 to view the entire programme with slides. After completing “JAK Inhibitors in the Management of Dermatologic Disorders: Clinical Implications of the Latest Safety Findings”, participants will be able to: Describe the patient demographics in the safety studies for Janus kinase (JAK) inhibitors; Summarise key safety data for approved and emerging JAK inhibitors in patients with atopic dermatitis (AD) or alopecia areata (AA); Use clinical and patient characteristics in the context of AD or AA to determine appropriate benefit and risk profiles when considering the use of a JAK inhibitor.
Comments 
loading
In Channel
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

JAK Inhibitors in the Management of Dermatologic Disorders: Clinical Implications of the Latest Safety Findings

JAK Inhibitors in the Management of Dermatologic Disorders: Clinical Implications of the Latest Safety Findings

PeerVoice